ABOUT GID BIO
GID BIO, Inc. is a global leader in cellular therapy, offering a tissue processing platform that enables cell-based treatments for a broad range of therapies. Our team of seasoned executives, adipose tissue scientists and surgeons works together to discover reliable, cost-effective solutions that utilize patients’ own cells as a treatment option.
Our Team
All Members
HR & Accounts
Sales & Marketing
IT Support
Roy J. Bostock
Chairman of the Board
Roy is an investor and businessman who has helped lead numerous global enterprises spanning the fields of advertising, aerospace, manufacturing, technology and finance. Bostock had a long and successful career in the advertising arena, which included engineering a merger to form the seventh largest global agency group, later acquired by Publicis Groupe in Paris. Bostock later was named Chairman of Northwest Airlines following its emergence from bankruptcy and helped architect the merger of Northwest and Delta Airlines, becoming Vice Chairman of Delta. Bostock also served as Chairman of Yahoo! Inc. and as a director of Morgan Stanley. Today, he is Chairman of his investment firm, Sealedge Investments, LLC. He graduated Phi Beta Kappa from Duke University, which he attended on a football scholarship and played both football and baseball while majoring in English literature. He earned an MBA from Harvard University.
William Cimino
CEO, Board of Directors
William Cimino, PhD, is CEO of The GID Group and an experienced medical device executive specializing in medical design and business development. Cimino has over 30 years of professional experience in all aspects of the medical device business. He has been directly responsible for the design and market introduction of over 50 medical products and has formed and run successful medical device startup companies.
Dale Tomrdle
SVP of Operations and Finance, Treasurer
Dale Tomrdle is the senior vice president of operations and finance of The GID Group and has 30 years of business leadership experience. Tomrdle has held executive and founding positions with both venture- and angel-backed startups, as well as led operations, finance, IT, business development and sales organizations at startup and large public companies.
Most recently, he worked with clients ranging from international Fortune 200 companies to startups.
Frank DiLazzaro
SVP of Global Business Development
Frank DiLazzaro is senior vice president of global business development at The GID Group and has worked in the health care industry for 30 years. DiLazzaro has held numerous executive positions focusing on sales and marketing, product development, operations and management. He has a strong global background, including global president of sales for Sytagenix Wound Management, and has built sales organizations in many key healthcare markets.
Abby Holewinski
Clinical Research Manager
Abby has spent the last five years of her career overseeing clinical studies at sites of varying sizes, including medical device startups and large universities. At GID BIO she is responsible for managing clinical research, from site review to initiation, to test the biotech company's cellular therapy in studies with FDA clearance. Prior to joining GID, Abby oversaw six pivotal device trials; three device post-approval studies; and three investigator-initiated studies from the clinical site level at Washington University School of Medicine in St. Louis and University of Colorado - Anschutz Medical School; and a sponsor-level trial at Obalon Therapeutics. Abby earned a master of science degree in nutrition from Saint Louis University.
Victoria Good, PhD
Director Clinical Affairs
Victoria began her tenure with GID BIO in 2015. She helped design a safety and feasibility trial and a pivotal trial to test GID’s stromal vascular fraction treatment for knee osteoarthritis. Her focus is on clinical trial design in support of therapeutic areas including osteoarthritis of the hand and shoulder; rheumatoid arthritis of the hand; diabetic ulcers; diabetic neuropathy; kidney fibrosis; and erectile dysfunction.
Victoria has over 24 years of experience in medical device research with participation in over 50 publications including peer-reviewed journals and societal presentations on devices. She began her career conducting simulator testing of hip and knee implants at Loma Linda University before devoting the last 15 years to developing and managing clinical trials at Zeiss, Covidien, Sonoma Orthopedics and GID BIO for ophthalmic diagnostics; respiratory and monitoring devices; orthopedic implants; and cellular biologics.
Victoria earned a bachelor of science degree in physics from California State University - San Bernardino and a Ph.D. in bioengineering from Strathclyde University with an emphasis on orthopaedic tribology (study of wear, friction and lubrication).
Adam Katz, MD
Founder, Board of Directors
Dr. Katz is Professor of Plastic Surgery and Director of the Research Laboratory in the Department of Plastic and Reconstructive Surgery, Wake Forest School of Medicine. He is internationally recognized for his contributions, innovations, and expertise in the science and translation of adipose-derived cell therapies and fat grafting, including the development of device platforms that enable such. In addition to his scientific and entrepreneurial endeavors, he maintains a clinical practice that comprises both reconstructive and aesthetic surgery. He mentors and instructs students and residents at all levels in both the laboratory and clinical setting.
Claire Tillyer, PhD
Clinical and Training Specialist
Claire has been a scientist for 20 years including working as a forensic DNA analyst for Cellmark Forensics in the UK and US. For GID BIO she works as a clinical and training specialist, designing and implementing training courses, with a particular emphasis on e-learning, as well as hands-on training in the operating theatre. She also carries out research and development and IT projects. She has worked in field applications and training development for several molecular biology companies including Qiagen, Oxford Immunotec and Cepheid (Danaher) in the EU and EMEA. She also works on projects to expand Coronavirus (SARS-CoV-2) testing capacities, including the development of a 20-minute SARS-CoV-2 test. Claire earned an undergraduate degree in forensic science and law; a postgraduate certificate in research methods, and a Ph.D. in molecular biology.
J. William Futrell, MD
Founder, Board of Directors
J. William Futrell, MD, is co-founder and chairman of The GID Group. As an entrepreneur, he is a co-inventor of multiple patents and a co-founder of numerous businesses,
including CellSource, Inc., StemSource, Inc., Human Analytix, Inc., Illumineer, Inc. and Life Science Enhancement Corporation. Futrell was professor and chief of plastic surgery at the University of Pittsburgh Medical Center for 21 years and a past president of the American Association of Plastic Surgeons.
Edwin Mendieta
Board of Directors
Edwin Mendieta is corporate counsel of the Pellas Group, one of the largest and most diversified business conglomerates in Central America. He has extensive experience in corporate law, focusing his practice on cross-border mergers and acquisitions, foreign investment, real estate development and banking. Mendieta is a member of the Board of Directors of INIDEM (Instituto Internacional de Derecho y Empresa), an academic institution around law and business.
G. Patrick Maxwell, MD
Founder
G. Patrick Maxwell, MD, is a world-renowned plastic surgeon known for his achievements in aesthetic surgery and is a pioneer of microsurgery. He holds 10 US patents — with seven more pending — for medical devices, has written over 100 scientific articles and performed live surgical demonstrations in over 20 countries. He invented the textured tissue expander, which has been used worldwide for breast reconstruction for 20 years, and developed flap procedures.
Morgan St. John
Board of Directors
Morgan St. John is the managing partner of Wyvern Capital and has been active in merchant and investment banking since 1978. He has originated, analyzed, structured, negotiated and syndicated approximately $40 billion of corporate transactions globally.
Prior to Wyvern Capital, St. John was a partner and managing director at Bankers Trust Company, where he built groups to become industry leaders in highly structured acquisition financing.
Ramón Llull, MD, PhD
Founder
Ramón Llull, MD, PhD, is currently director of the STEM Center in Mallorca, Spain, providing advanced regenerative therapies based on adipose biotechnology. Along with Dr. Adam Katz, Llull co-holds several international and US patents related to tissue engineering, device biotechnology and stem cells. He is a founder and past chairman of the International Federation of Adipose Technologies and Science (IFATS) and a founder of StemSource, Inc.
